Psilocybin and palliative end-of-life care

Abstract

2 Journal of Psychopharmacology administration of the drug on only one or a few occasions, obviating concerns about medication adherence, and transient acute and adverse effects. However, the path forward is not a simple one—larger-scale, controlled, Phase III studies …